Publications
5813 Results
- Journal / Conference
- JCO Oncol Pract. 2025 Oct;21(10):1512-1521. doi: 10.1200/OP-24-00902. Epub 2025 Mar 13.NIHMS2055153
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID40080774
- PMC
- PMC12347083
Screening and Referral for Health-Related Social Needs and Financial Distress: Current Processes Among National Cancer Institute Community Oncology Research Program Practices
- Journal / Conference
- Breast. 2025 Oct;83:104547. doi: 10.1016/j.breast.2025.104547. Epub 2025 Jul 26.
- Year
- 2025
- Research Committee(s)
- Cancer Survivorship
- PMID
- PMID40743662
- PMC
- PMC12336806
- Study Number(s)
- CTSU/A221405
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial (IBCSG 48-14/BIG 08-13/Alliance A221405)
- Journal / Conference
- J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):49-55. doi: 10.1093/jncimonographs/lgae044
- Year
- 2025
- Research Committee(s)
- Cancer Control
- PMID
- PMID39989045
- PMC
- PMC11848038
- Study Number(s)
- SWOG-9217
Challenges to and considerations of designing cancer prevention trials
- Journal / Conference
- NPJ Breast Cancer. 2025 Mar 8;11(1):24. doi: 10.1038/s41523-025-00740-z
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID40057511
- PMC
- PMC11890565
- Study Number(s)
- CTSU/C40603
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets
- Journal / Conference
- Ann Oncol. 2025 Apr;36(4):403-413. doi: 10.1016/j.annonc.2024.12.010. Epub 2024 Dec 18.NIHMS2052322
- Year
- 2025
- Research Committee(s)
- Breast
- PMID
- PMID39706338
- PMC
- PMC11949722
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
- Journal / Conference
- Genome Med. 2025 May 12;17(1):53. doi: 10.1186/s13073-025-01468-y
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID40355948
- PMC
- PMC12070537
Patient rights in precision oncology: right treatment, right time, right dose, right order, right place
- Journal / Conference
- J Clin Oncol. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4.
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID40906970
- PMC
- PMC12509457
- Study Number(s)
- CTSU/C80405
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
- Journal / Conference
- JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6.NIHMS2058197
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39913886
- PMC
- PMC12002398
- Study Number(s)
- CTSU/EAY131
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
- Journal / Conference
- Clin Cancer Res. 2025 Oct 15;31(20):4299-4310. doi: 10.1158/1078-0432.CCR-24-3531.NIHMS2084882
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID40388547
- PMC
- PMC12383705
- Study Number(s)
- CTSU/EAY131
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
- Journal / Conference
- J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049
- Year
- 2025
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID39989037
- PMC
- PMC11848039
- Study Number(s)
- CTSU/EA1151